Tumor-targeting Antigen
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
51
NCT07190833
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2025
Completion: Dec 31, 2030
NCT07170592
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Start: Dec 31, 2025
Loading map...